Anti-TR10B/ TRAIL-R2/ TNFRSF10B monoclonal antibody

Anti-TR10B/ TRAIL-R2/ TNFRSF10B antibody for FACS & in-vivo assay

Target products collectionGo to TRAIL-R2/TNFRSF10B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T70067-Ab-1/ GM-Tg-hg-T70067-Ab-2Anti-Human TRAIL-R2/TNFRSF10B monoclonal antibodyHuman
GM-Tg-rg-T70067-Ab-1/ GM-Tg-rg-T70067-Ab-2Anti-Rat TRAIL-R2/TNFRSF10B monoclonal antibodyRat
GM-Tg-mg-T70067-Ab-1/ GM-Tg-mg-T70067-Ab-2Anti-Mouse TRAIL-R2/TNFRSF10B monoclonal antibodyMouse
GM-Tg-cynog-T70067-Ab-1/ GM-Tg-cynog-T70067-Ab-2Anti-Cynomolgus/ Rhesus macaque TRAIL-R2/TNFRSF10B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T70067-Ab-1/ GM-Tg-felg-T70067-Ab-2Anti-Feline TRAIL-R2/TNFRSF10B monoclonal antibodyFeline
GM-Tg-cang-T70067-Ab-1/ GM-Tg-cang-T70067-Ab-2Anti-Canine TRAIL-R2/TNFRSF10B monoclonal antibodyCanine
GM-Tg-bovg-T70067-Ab-1/ GM-Tg-bovg-T70067-Ab-2Anti-Bovine TRAIL-R2/TNFRSF10B monoclonal antibodyBovine
GM-Tg-equg-T70067-Ab-1/ GM-Tg-equg-T70067-Ab-2Anti-Equine TRAIL-R2/TNFRSF10B monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T70067-Ab-1/ GM-Tg-hg-T70067-Ab-2; GM-Tg-rg-T70067-Ab-1/ GM-Tg-rg-T70067-Ab-2;
GM-Tg-mg-T70067-Ab-1/ GM-Tg-mg-T70067-Ab-2; GM-Tg-cynog-T70067-Ab-1/ GM-Tg-cynog-T70067-Ab-2;
GM-Tg-felg-T70067-Ab-1/ GM-Tg-felg-T70067-Ab-2; GM-Tg-cang-T70067-Ab-1/ GM-Tg-cang-T70067-Ab-2;
GM-Tg-bovg-T70067-Ab-1/ GM-Tg-bovg-T70067-Ab-2; GM-Tg-equg-T70067-Ab-1/ GM-Tg-equg-T70067-Ab-2
Products NameAnti-TRAIL-R2/TNFRSF10B monoclonal antibody
Formatmab
Target NameTRAIL-R2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-TRAIL-R2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-117Pre-Made Conatumumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
    BiosimilarGMP-Bios-ab-574Pre-Made Tilogotamab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
    BiosimilarGMP-Bios-INN-829Pre-Made Eftozanermin Alfa Biosimilar, Fusion Protein targeting TNFRSF10B/TRAIL-R2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD262/DR5/KILLER/KILLER/DR5/TRICK2/TRICK2A/TRICK2B/TRICKB/ZTNFR9
    BiosimilarGMP-Bios-ab-156Pre-Made Drozitumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
    BiosimilarGMP-Bios-ab-571Pre-Made Tigatuzumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
    BiosimilarGMP-Bios-ab-060Pre-Made Benufutamab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
    BiosimilarGMP-Bios-ab-309Pre-Made Lexatumumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species TR10B/ TRAIL-R2/ TNFRSF10B VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T70067-Ag-1tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B) protein
    ORF Viral VectorpGMLV000251human TNFRSF10B Lentivirus plasmid
    ORF Viral VectorvGMLV000251human TNFRSF10B Lentivirus particle
    ORF Viral VectorpGMLV000794house mouse Tnfrsf10b Lentivirus plasmid
    ORF Viral VectorpGMAAV000358Norway rat Tnfrsf10b AAV plasmid
    ORF Viral VectorpGMLPm002792mouse Tnfrsf10b Lentivirus plasmid
    ORF Viral VectorvGMLV000794house mouse Tnfrsf10b Lentivirus particle
    ORF Viral VectorvGMAAV000358Norway rat Tnfrsf10b AAV particle
    ORF Viral VectorvGMLPm002792mouse Tnfrsf10b Lentivirus particle


    Target information

    Target IDGM-T70067
    Target NameTRAIL-R2
    Gene ID8795,21933,716650,100057812
    Gene Symbol and SynonymsCD262,DR5,KILLER,KILLER/DR5,Ly98,MK,TNFRSF10B,TRAIL-R2,TRAILR2,TRICK2,TRICK2A,TRICK2B,TRICKB,ZTNFR9
    Uniprot AccessionO14763
    Uniprot Entry NameTR10B_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseCancer
    Gene EnsemblENSG00000120889
    Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)

    The target: TRAIL-R2, gene name: TNFRSF10B, also named as CD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9. The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for this gene. [provided by RefSeq, Mar 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.